The Efficacy of Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate efficacy of biomarker in patient with interstitial cystitis/painful bladder syndrome

Detailed Description
-----------------
This is a observational study

Official Title
-----------------
Experimental Study of Biomarker in Patient With Interstitial Cystitis/Painful Bladder

Conditions
-----------------
Interstitial Cystitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study 2) Pain VAS ≥4 3) O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2) 4) PUF score ≥ 13 5) cystoscopic record within 2 years Exclusion Criteria: Patients who are pregnancy or, childbearing age without no contraception Patients with voided volume <40 or, > 400ml Patients with microscopic hematuria, (≥1+ in dipstick), If not excluded that no evidence of neoplastic tumor examination Patients with urine culture showing evidence of urinary tract infection 1month prior to the study Accompanied medical problem below Tuberculosis in urinary system Bladder cancer, urethral cancer, prostate cancer Recurrent cystitis anatomical disorder Patients had prior surgery (eq, bladder augmentation, cystectomy Patients with neurologic disorder Patients with indwelling catheter or intermittent self-catheterization Patients with psychologic problem

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hunner's ulcer interstitial cystitis<br>Hunner's ulcer interstitial cystitis | |
| non-ulcer interstitial cystitis<br>non-ulcer interstitial cystitis | |
| Control<br>Control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare of expression of the biomarker such as APF, HB-EGF, MCP-1 among the Hunner's ulcer interstitial cystitis and non-ulcer interstitial cystitis and control groups | To compare of expression of the biomarker such as APF, HB-EGF, MCP-1 among the Hunner's ulcer interstitial cystitis and non-ulcer interstitial cystitis and control groups | 1month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare of changes voiding parameters after bladder biopsy between Hunner' ulcer group and non-ulcer group | To compare of changes voiding parameters after bladder biopsy between Hunner' ulcer group and non-ulcer group | 1 month | 
| TO compare of change of scores of questionnaires such as O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q), Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF), Visual Analogue Scale (Pain) between Hunner's ulcer group and non-ulcer group | TO compare of change of scores of questionnaires such as O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q), Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF), Visual Analogue Scale (Pain) between Hunner's ulcer group and non-ulcer group | 1month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biomarkers